Shares of Applied Molecular Transport Inc. (AMTI) were up 17.44% in pre-market trading at $34.0 at the time of writing. AMTI stock closed the last session at $28.95, down by -2.75% or $0.82. During the session, AMTI stock fluctuated between $27.61 and $32.6221. Its daily volume, 0.4 million shares, performed better than its 50-day volume of 0.22 million shares as well as its year-to-date volume of 0.22 million shares.
AMTI stock has gained 36.17% over the last 12 months and has added 3.28% in the last week. Over the last six months, AMTI stock has decreased by -31.11 percent, and over the last three months, it has fallen by -36.72%. AMTI stock has so far returned -5.91% this year. A major event is scheduled for this week, which is boosting AMTI stock.
AMTI will participate in which event?
Applied Molecular is a clinical-stage biopharmaceutical company developing novel oral biologic products to treat autoimmune, inflammatory, metabolic, and other diseases using its proprietary technology platform. AMT’s proprietary technology platform allows it to exploit natural cellular trafficking pathways in order to facilitate the active crossing of intestinal epithelial barriers (IE) for diverse therapeutic modalities. An active transport mechanism enables the material to cross the IE barrier using the cell’s own machinery.
AMTI’s ability to utilize this mechanism is one of the key components of its differentiation strategy. Additional biologic products in patient-friendly oral forms are being developed by AMTI that address specific biological aspects of gastrointestinal diseases directly or enter the systemic circulation to effectively target specific biological phenomena. South San Francisco, CA, is where AMTI’s headquarters, internal manufacturing facilities, and lab are located.
As part of Canaccord Genuity’s 41st Annual Growth Conference on Wednesday, August 11, 2021, at 2:30 pm ET, co-founder and chief executive Tahir Mahmood, Ph.D., will participate in a fireside chat, announced Applied Molecular this past Friday. A live webcast of the event will be available at https://ir.appliedmt.com/news-events/events via the AMTI website. For 30 days following the meeting, the AMTI presentation will be archived.
There was recently new Phase 1b data released by Applied Molecular for AMT-101 in patients with ulcerative colitis (UC). AMT-101 combines hIL-10 and AMT’s proprietary carrier molecule into GI-selective, oral formulation. An AMTI poster at the European Crohn’s and Colitis Organisation (ECCO)’21 Virtual Congress covered the results from a Phase 1b trial of AMT-101, a gut selective orally available IL-10.
AMTI Stock continues to move forward:
Further data from these studies support AMTI’s strategic plan to analyze oral AMT-101 in both IBD and RA studies over a longer period of time in Phase 2. The Phase 1b results presented by Applied Molecular (AMTI) have driven the design of four global clinical trials to maximize the benefit for patients while enabling data generation in patients undergoing both monotherapy and combination protocols in both biologic-naive and -experienced settings.
